Carlos Costa - Sep 20, 2024 Form 4 Insider Report for Foghorn Therapeutics Inc. (FHTX)

Role
Chief People Officer
Signature
/s/ Michael LaCascia, Attorney-in-Fact for Carlos Costa
Stock symbol
FHTX
Transactions as of
Sep 20, 2024
Transactions value $
-$231,506
Form type
4
Date filed
9/24/2024, 04:01 PM
Previous filing
Sep 20, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FHTX Common Stock Options Exercise $133K +35.8K $3.72 35.8K Sep 20, 2024 Direct F1
transaction FHTX Common Stock Sale -$359K -35.8K -100% $10.04 0 Sep 20, 2024 Direct F1, F2
transaction FHTX Common Stock Options Exercise $3.19K +857 $3.72 857 Sep 23, 2024 Direct F1
transaction FHTX Common Stock Sale -$8.72K -857 -100% $10.17 0 Sep 23, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FHTX Stock Option (right to buy) Options Exercise $0 -35.8K -46.8% $0.00 40.6K Sep 20, 2024 Common Stock 35.8K $3.72 Direct F1, F3
transaction FHTX Stock Option (right to buy) Options Exercise $0 -857 -2.11% $0.00 39.8K Sep 23, 2024 Common Stock 857 $3.72 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on March 11, 2024.
F2 The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $10.00 to $10.22 per share.
F3 The option vested as to 25% of the underlying shares of common stock on August 29, 2019, and at a rate of 6.25% of the underlying shares thereafter on the first day of each calendar quarter following such first anniversary until the option was fully vested.